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ABSTRACT	  Regulatory	  T	  cells	  (Tregs)	  are	  required	  for	  the	  induction	  and	  maintenance	  of	  immune	  homeostasis.	  Singh	  et	  al.	  demonstrated	  that	  depletion	  of	  Tregs	  in	  mice	  results	  in	  a	  loss	  of	  self-­‐tolerance	  that	  manifests	  in	  the	  development	  of	  autoimmune	  diseases	  such	  as	  Inflammatory	  Bowel	  Disease	  (IBD)	  [1].	  In	  humans,	  autoimmune	  diseases	  such	  as	  IBD,	  Multiple	  Sclerosis	  (MS),	  and	  Type	  1	  Diabetes	  are	  thought	  to	  occur	  due	  to	  a	  deficiency	  in	  the	  number	  or	  function	  of	  Tregs	  [2].	  The	  importance	  of	  Tregs	  in	  modulating	  the	  human	  immune	  system	  is	  perhaps	  best	  exemplified	  by	  IPEX	  (immune	  dysregulation,	  polyendocrinopathy,	  enteropathy,	  x-­‐linked	  syndrome),	  a	  severe	  autoimmune	  disease	  characterized	  by	  a	  defect	  in	  the	  key	  Treg	  transcription	  factor	  Foxp3	  [3].	  Tregs	  unquestionably	  play	  an	  important	  role	  in	  regulating	  the	  immune	  system,	  but	  there	  is	  still	  more	  to	  learn	  about	  how	  Tregs	  are	  induced.	  In	  recent	  years,	  vitamin	  D	  has	  been	  identified	  as	  an	  important	  immunomodulatory	  molecule	  that	  may	  promote	  Treg	  differentiation	  [4].	  In	  vitro	  studies	  have	  confirmed	  that	  vitamin	  D	  inhibits	  T	  cell	  proliferation	  and	  regulates	  dendritic	  cell	  (DC)	  maturation	  to	  promote	  a	  tolerogenic	  phenotype	  [5,	  6].	  Moreover,	  vitamin	  D	  deficiency	  is	  associated	  with	  an	  increased	  risk	  in	  the	  development	  of	  autoimmune	  diseases	  such	  as	  MS	  and	  Type	  1	  Diabetes	  [3,	  7-­‐10].	  	  
	  	  viii	  
Our	  goal	  was	  to	  test	  the	  hypothesis	  that	  vitamin	  D	  enhances	  human	  Treg	  differentiation	  and	  to	  elucidate	  the	  mechanism	  by	  which	  vitamin	  D	  modulates	  immune	  responses.	  Here	  we	  report	  that	  there	  is	  a	  positive	  correlation	  between	  the	  serum	  concentration	  of	  vitamin	  D	  and	  the	  Treg	  frequency	  in	  adult	  peripheral	  blood.	  To	  further	  study	  the	  effect	  of	  vitamin	  D	  on	  human	  Treg	  differentiation,	  we	  used	  an	  
ex	  vivo	  culture	  system	  to	  induce	  Tregs	  from	  human	  umbilical	  cord	  blood	  (UCB).	  We	  found	  that	  supplementation	  of	  vitamin	  D	  to	  human	  UCB	  enhanced	  Treg	  differentiation.	  Furthermore,	  addition	  of	  a	  vitamin	  D	  receptor	  inhibitor	  to	  human	  UCB	  decreased	  Treg	  differentiation.	  Taken	  together,	  these	  data	  indicate	  that	  vitamin	  D	  has	  a	  positive	  effect	  on	  human	  Treg	  differentiation.	  Additionally,	  our	  data	  suggest	  that	  vitamin	  D	  exerts	  its	  immunomodulatory	  effects	  by	  acting	  on	  monocytes.	  Vitamin	  D	  supplementation	  enhanced	  the	  expression	  of	  the	  monocyte	  cell	  surface	  molecule	  Neuropilin-­‐1	  (NRP-­‐1),	  which	  functions	  to	  bind	  TGF-­‐β	  at	  the	  cell	  surface	  [11].	  TGF-­‐β	  is	  an	  essential	  immunomodulatory	  cytokine	  to	  induce	  Tregs	  in	  this	  culture	  system.	  We	  concluded	  that	  vitamin	  D	  enhances	  human	  Treg	  differentiation	  in	  part	  by	  altering	  the	  phenotype	  of	  monocytes	  to	  promote	  the	  expression	  of	  cell	  surface	  molecules	  important	  for	  Treg	  differentiation.	  The	  work	  encompassed	  here	  will	  contribute	  to	  our	  understanding	  of	  vitamin	  D	  as	  an	  immunomodulatory	  molecule	  and	  potentially	  aid	  scientific	  efforts	  to	  develop	  new	  therapeutics	  to	  treat	  autoimmune	  disease.	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CHAPTER	  ONE	  LITERATURE	  REVIEW	  Gershon	  and	  Kondo’s	  experiments	  in	  the	  early	  70’s	  suggested	  that	  thymus-­‐derived	  lymphocytes	  were	  essential	  for	  the	  induction	  of	  immunological	  tolerance	  [12,	  13].	  Many	  investigators	  worked	  to	  delineate	  the	  cell	  population	  responsible	  for	  this	  phenomenon,	  and	  to	  this	  end,	  Tada	  identified	  suppressor	  T	  cells	  as	  a	  key	  thymus-­‐derived	  cell	  subset	  responsible	  for	  the	  induction	  of	  immunological	  tolerance	  [14,	  15].	  Tada	  argued	  that	  suppressor	  T	  cells	  were	  a	  functionally	  distinct	  T	  cell	  subset	  that	  worked	  to	  suppress	  antigen	  induced	  CD4+	  T	  helper	  cell	  responses	  as	  well	  as	  antibody	  responses	  [16,	  17].	  Moreover,	  Tada	  was	  one	  of	  the	  first	  to	  suggest	  that	  the	  inability	  of	  tumor	  bearing	  animals	  to	  mount	  an	  effective	  anti-­‐tumor	  immune	  response	  was	  due	  to	  the	  active	  suppression	  of	  tumor	  immunity	  via	  suppressor	  T	  cells	  rather	  than	  a	  general	  state	  of	  immune	  unresponsiveness	  in	  these	  animals	  [18].Tada’s	  work	  to	  further	  characterize	  suppressor	  T	  cells	  and	  to	  understand	  the	  mechanism	  of	  T	  cell	  mediated	  suppression	  was	  heavily	  challenged	  due	  to	  the	  inability	  to	  identify	  specific	  markers	  that	  could	  distinguish	  this	  population	  of	  T	  cells	  [19].	  As	  a	  result,	  the	  hunt	  to	  understand	  the	  basis	  of	  immunological	  tolerance	  and	  the	  role	  of	  suppressor	  T	  cells	  was	  largely	  abandoned	  for	  some	  time.	  	  Later	  work	  by	  Sakaguchi	  sparked	  a	  renewed	  interest	  in	  the	  study	  of	  immune	  regulation	  and	  tolerance.	  Sakaguchi	  discovered	  and	  characterized	  a	  new	  subset	  of	  
	  	  
2	  cells	  named	  regulatory	  T	  cells	  that	  were	  functionally	  similar	  to	  Tada’s	  suppressor	  T	  cells.	  Sakaguchi	  et	  al.	  determined	  that	  T	  cells	  expressing	  the	  IL-­‐2	  receptor	  CD25	  had	  regulatory	  activity	  by	  inoculating	  BALB/c	  athymic	  nude	  mice	  with	  CD4+	  cell	  suspensions	  prepared	  from	  the	  lymph	  nodes	  and	  spleens	  of	  BALB/c	  nu/+	  mice	  and	  depleted	  of	  CD25+	  cells.	  All	  recipients	  of	  the	  CD25+	  depleted	  cell	  suspensions	  developed	  autoimmune	  disease.	  Reconstitution	  of	  the	  CD4+CD25+	  cell	  population	  within	  a	  certain	  amount	  of	  time	  prevented	  the	  development	  of	  autoimmune	  disease	  [20].	  A	  decade	  after	  Tada’s	  work	  arguing	  for	  the	  existence	  of	  suppressor	  T	  cells,	  Sakaguchi	  finally	  solidified	  the	  role	  of	  T	  cell	  mediated	  suppression	  in	  the	  induction	  of	  immunological	  tolerance.	  Moreover,	  Sakaguchi’s	  work	  was	  fundamental	  in	  characterizing	  CD4+CD25+	  regulatory	  T	  cells.	  Our	  understanding	  of	  regulatory	  T	  cells	  was	  further	  advanced	  by	  the	  discovery	  that	  the	  transcription	  factor	  Foxp3	  was	  the	  master	  regulator	  of	  Tregs.	  Hori	  et	  al.	  discovered	  that	  naïve	  T	  cells	  were	  converted	  to	  a	  regulatory	  phenotype	  after	  the	  induced	  expression	  of	  Foxp3	  via	  retroviral	  gene	  transfer	  [21].	  The	  importance	  of	  Foxp3+	  Tregs	  in	  modulating	  the	  human	  immune	  system	  is	  perhaps	  best	  exemplified	  by	  IPEX,	  a	  severe	  autoimmune	  disease	  characterized	  by	  a	  defect	  in	  Foxp3	  [3].	  Loss	  of	  function	  of	  Foxp3	  in	  mice	  also	  leads	  to	  the	  development	  of	  autoimmune	  disorders	  as	  seen	  in	  Scurfy	  mice	  [22].	  In	  humans,	  other	  autoimmune	  diseases	  such	  as	  IBD,	  MS,	  and	  Type	  1	  Diabetes	  are	  thought	  to	  occur	  due	  to	  a	  deficiency	  in	  the	  number	  or	  function	  of	  Foxp3+	  Tregs	  [2].	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Naturally	  arising	  Tregs	  (nTregs)	  are	  generated	  in	  the	  thymus	  whereas	  inducible	  Tregs	  (iTregs)	  are	  generated	  in	  the	  periphery.	  Various	  factors	  influence	  the	  generation	  and	  function	  of	  iTregs	  including	  the	  vitamin	  A	  metabolite	  retinoic	  acid	  (RA)	  and	  TGF-­‐β	  [23].The	  cytokine	  TGF-­‐β	  is	  produced	  in	  a	  latent	  form	  that	  must	  be	  activated	  in	  order	  to	  exert	  its	  biological	  effects.	  Non	  covalent	  interactions	  between	  latent	  TGF-­‐β	  and	  latency	  associated	  peptide	  (LAP)	  render	  the	  cytokine	  inactive	  [24].	  TGF-­‐β	  is	  activated	  upon	  proteolytic	  separation	  from	  LAP,	  and	  signals	  through	  SMADs	  to	  influence	  cellular	  transcription.	  Xiao	  et	  al.	  discovered	  that	  RA	  promotes	  the	  generation	  of	  Foxp3+	  Tregs	  by	  increasing	  the	  expression	  and	  phosphorylation	  of	  SMAD3,	  a	  key	  component	  in	  the	  TGF-­‐β	  signaling	  pathway	  [25].	  Furthermore,	  Nakamura	  et	  al.	  showed	  that	  CD4+CD25+	  cells	  expressed	  TGF-­‐β	  at	  the	  cell	  surface	  and	  suppressed	  CD4+CD25-­‐	  cells.	  Addition	  of	  anti-­‐TGF-­‐β	  abolished	  the	  suppressive	  function	  of	  the	  CD4+CD25+	  population	  [26].	  Taken	  together,	  these	  findings	  indicate	  that	  TGF-­‐β	  is	  a	  critical	  factor	  for	  the	  generation	  and	  function	  of	  Tregs.	   Recently,	  vitamin	  D	  has	  been	  shown	  to	  have	  an	  effect	  on	  Treg	  differentiation.	  Urry	  et	  al.	  discovered	  that	  vitamin	  D	  supplementation	  increased	  the	  frequency	  of	  Foxp3+	  Tregs	  in	  vitro	  [27].	  Indeed,	  vitamin	  D	  is	  considered	  to	  be	  an	  immunomodulatory	  molecule	  and	  vitamin	  D	  deficiency	  is	  associated	  with	  an	  increased	  risk	  in	  the	  development	  of	  autoimmune	  diseases	  such	  as	  MS	  [2[10]].	  Moreover,	  vitamin	  D	  supplementation	  has	  been	  shown	  to	  inhibit	  the	  development	  of	  experimental	  autoimmune	  encephalomyelitis	  (EAE),	  a	  murine	  model	  of	  MS	  [3,	  7,	  8].	  
	  	  
4	  Additionally,	  vitamin	  D	  has	  been	  shown	  to	  slow	  the	  loss	  of	  renal-­‐allograft	  function	  in	  kidney	  transplant	  patients,	  suggesting	  that	  the	  immunomodulatory	  properties	  of	  vitamin	  D	  may	  be	  harnessed	  in	  the	  future	  to	  prevent	  or	  slow	  graft	  rejection	  [9].	  While	  vitamin	  D	  is	  considered	  to	  be	  an	  immunomodulatory	  molecule,	  the	  exact	  mechanisms	  underlying	  its	  immunosuppressive	  function	  are	  yet	  to	  be	  elucidated.	  	  	   Humans	  acquire	  vitamin	  D	  through	  dietary	  intake	  or	  by	  exposure	  to	  sunlight.	  Vitamin	  D	  is	  metabolized	  to	  its	  biologically	  active	  form	  by	  hydroxylation	  in	  the	  liver	  and	  kidney.	  In	  the	  liver,	  vitamin	  D	  is	  metabolized	  by	  the	  enzyme	  25-­‐hydroxylase	  to	  form	  25-­‐hydroxyvitamin	  D-­‐3,	  the	  predominant	  form	  of	  vitamin	  D	  in	  the	  circulation.	  Next,	  25-­‐	  hydroxyvitamin	  D-­‐3	  is	  metabolized	  in	  the	  kidney	  by	  the	  enzyme	  1-­‐α-­‐	  hydroxylase	  to	  form	  1,25-­‐dihydroxyvitamin	  D-­‐3,	  the	  biologically	  active	  form	  of	  the	  molecule.	  1,25-­‐dihydroxyvitamin	  D-­‐3	  crosses	  the	  plasma	  membrane	  of	  a	  cell	  and	  binds	  to	  the	  nuclear	  vitamin	  D	  receptor	  (VDR).	  The	  VDR	  forms	  a	  heterodimer	  with	  the	  retinoic	  acid-­‐X-­‐receptor	  and	  binds	  to	  the	  vitamin	  D	  responsive	  element	  (VDRE)	  in	  DNA,	  leading	  to	  the	  alteration	  of	  gene	  transcription	  [3,	  4].	  	  Various	  immune	  cells	  such	  as	  T	  and	  B	  lymphocytes,	  monocytes,	  macrophages,	  and	  DC’s	  express	  a	  VDR	  and	  are	  therefore	  capable	  of	  responding	  to	  vitamin	  D	  [7].	  Kang	  et	  al.	  demonstrated	  that	  1,25-­‐dihydroxyvitamin	  D3	  promoted	  Foxp3	  expression	  in	  CD4+	  T	  cells.	  After	  vitamin	  D	  supplementation,	  the	  VDR	  bound	  directly	  to	  the	  VDRE	  within	  the	  Foxp3	  gene	  to	  enhance	  promoter	  activity	  [28].	  Additionally,	  Mayne	  et	  al.	  investigated	  the	  ability	  of	  vitamin	  D	  to	  inhibit	  EAE	  by	  acting	  on	  the	  VDR	  in	  CD4+	  T	  cells.	  The	  incidence	  of	  EAE	  in	  mice	  with	  a	  functional	  
	   	   	   	  
	  
5	  VDR	  in	  CD4+	  T	  cells	  was	  decreased	  upon	  vitamin	  D	  supplementation.	  VDR	  gene	  inactivation	  in	  CD4+	  T	  cells	  prevented	  this	  phenomenon,	  indicating	  that	  vitamin	  D	  can	  act	  on	  CD4+	  T	  cells	  via	  the	  VDR	  to	  inhibit	  EAE	  [29].	  	  Other	  studies	  have	  suggested	  that	  vitamin	  D	  can	  act	  on	  antigen	  presenting	  cells	  to	  influence	  Treg	  differentiation.	  Van	  der	  Aar	  et	  al.	  showed	  that	  immature	  dendritic	  cells	  stimulated	  with	  1,25-­‐dihydroxyvitamin	  D3	  adopted	  a	  tolerogenic	  phenotype	  that	  promoted	  Treg	  differentiation	  in	  co-­‐cultures	  with	  naïve	  CD4+	  T	  cells	  [5].	  Additionally,	  Ferreira	  et	  al.	  studied	  the	  effects	  of	  addition	  of	  1,25-­‐dihydroxyvitamin	  D3	  on	  dendritic	  cell	  differentiation	  from	  the	  bone	  marrow	  cells	  of	  C57/Bl/6	  mice.	  Dendritic	  cells	  differentiated	  in	  the	  presence	  of	  vitamin	  D	  displayed	  decreased	  levels	  of	  the	  DC	  activation	  markers	  MHCII,	  CD80,	  and	  CD86	  as	  compared	  to	  control	  DC’s	  differentiated	  in	  the	  absence	  of	  vitamin	  D.	  Moreover,	  the	  ability	  of	  the	  vitamin	  D	  treated	  DC’s	  to	  stimulate	  T	  cell	  proliferation	  in	  vitro	  was	  reduced	  as	  compared	  to	  control	  DC’s	  [30].	  Taken	  together,	  these	  findings	  illustrate	  that	  vitamin	  D	  can	  act	  on	  antigen	  presenting	  cells	  to	  modulate	  the	  immune	  response.	  	  Leukocytes	  such	  as	  monocytes,	  macrophages,	  and	  DC’s	  are	  derived	  from	  hematopoietic	  stem	  cells	  (HSCs)	  in	  the	  bone	  marrow.	  HSCs	  give	  rise	  to	  lineage-­‐restricted	  progenitors	  such	  as	  the	  common	  myeloid	  progenitor	  (CMP)	  and	  the	  macrophage/DC	  progenitor	  (MDP)	  that	  have	  the	  potential	  to	  further	  differentiate	  into	  monocytes,	  macrophages	  or	  DC’s.	  Monocytes	  circulate	  through	  the	  blood	  and	  play	  an	  important	  role	  in	  innate	  immunity	  by	  producing	  cytokines	  and	  antimicrobial	  compounds	  that	  alert	  the	  immune	  system	  and	  combat	  the	  invading	  microorganism.	  
	   	   	   	  
	  
6	  Monocytes	  can	  also	  leave	  the	  circulation	  and	  enter	  tissues	  where	  they	  function	  as	  a	  precursor	  to	  macrophages	  and	  DC’s.	  Differentiation	  of	  monocytes	  to	  macrophages	  and	  DC’s	  in	  tissue	  is	  understood	  to	  happen	  during	  steady-­‐state	  conditions	  as	  well	  as	  in	  response	  to	  inflammation	  and	  bacterial	  infection.	  In	  mice,	  monocyte	  recruitment	  is	  required	  to	  combat	  infection	  by	  the	  intracellular	  bacterium	  Listeria	  
monocytogenes	  as	  well	  as	  other	  bacterial,	  viral,	  and	  fungal	  pathogens.	  Additionally,	  in	  humans	  approximately	  90%	  of	  monocytes	  express	  the	  cell	  surface	  molecule	  CD14,	  a	  Toll	  Like	  Receptor	  (TLR)	  that	  recognizes	  bacterial	  Lipopolysaccharide	  (LPS)	  and	  helps	  sound	  the	  alarm	  against	  bacterial	  invasion.	  Depending	  on	  the	  cytokine	  milieu,	  monocytes	  can	  either	  facilitate	  activation	  or	  inhibition	  of	  the	  immune	  response,	  and	  monocytes	  can	  also	  contribute	  to	  tissue	  healing	  [31-­‐34].	  	   In	  a	  recent	  manuscript	  currently	  under	  review,	  Jaeger	  et	  al.	  reported	  that	  monocytes	  expressing	  the	  cell	  surface	  molecule	  CD14	  and	  high	  levels	  of	  CD36	  were	  uniquely	  capable	  of	  inducing	  Foxp3+	  Tregs	  from	  naïve	  CD4+	  T	  cells	  in	  human	  UCB.	  The	  monocyte	  cell	  surface	  marker	  CD36	  is	  a	  receptor	  for	  the	  ligand	  thrombospondin-­‐1	  (TSP-­‐1).	  TSP-­‐1	  activates	  TGF-­‐β	  by	  binding	  to	  the	  LAP/latent	  TGF-­‐β	  complex	  and	  inducing	  a	  conformational	  change	  that	  somehow	  relieves	  the	  mature	  form	  of	  TGF-­‐β	  from	  the	  latent	  complex	  [35].	  In	  turn,	  TGF-­‐β	  is	  a	  critical	  factor	  for	  the	  generation	  of	  Tregs.	  Additionally,	  Jaeger	  et	  al.	  used	  human	  UCB	  to	  study	  Treg	  induction	  because	  UCB	  has	  a	  greater	  affinity	  for	  Treg	  differentiation	  than	  adult	  peripheral	  blood.	  Indeed,	  for	  over	  fifty	  years	  investigators	  have	  understood	  that	  mammals	  exposed	  to	  foreign	  tissue	  in-­‐utero	  have	  the	  ability	  to	  develop	  tolerance	  to	  
	   	   	   	  
	  
7	  the	  foreign	  homologous	  tissue.	  For	  example,	  Medawar	  and	  colleagues	  described	  an	  experiment	  where	  each	  of	  the	  six	  fetuses	  of	  a	  pregnant	  female	  CBA	  mouse	  were	  injected	  intra-­‐embryonically	  with	  cells	  from	  an	  adult	  male	  mouse	  of	  the	  A	  strain.	  Of	  the	  six	  fetuses,	  five	  healthy	  mice	  were	  born	  and	  all	  received	  skin	  grafts	  from	  an	  adult	  donor	  mouse	  of	  the	  A	  strain.	  The	  graft	  was	  accepted	  and	  incorporated	  into	  the	  skins	  of	  3	  of	  the	  five	  mice	  given	  the	  intra-­‐embryonic	  injections.	  Additionally,	  the	  graft	  was	  still	  intact	  at	  day	  11.	  In	  contrast,	  when	  adult	  CBA	  mice	  received	  a	  graft	  from	  an	  A-­‐line	  donor	  the	  graft	  was	  rejected	  in	  approximately	  12	  days	  [36].	  The	  work	  of	  Medawar	  and	  others	  was	  instrumental	  in	  understanding	  the	  phenomenon	  of	  neonatal	  tolerance.	  Additionally,	  Jaeger’s	  work	  sheds	  new	  light	  on	  our	  understanding	  of	  how	  neonatal	  tolerance	  is	  induced.	  	  We	  used	  the	  human	  UCB	  model	  established	  by	  Jaeger	  et	  al.	  to	  study	  the	  effect	  of	  vitamin	  D	  on	  immune	  regulation	  and	  Treg	  differentiation.	  We	  hypothesized	  that	  addition	  of	  vitamin	  D	  to	  UCB	  would	  enhance	  Treg	  differentiation.	  Additionally,	  we	  worked	  to	  determine	  a	  mechanism	  of	  action	  of	  vitamin	  D	  in	  immune	  modulation	  and	  Treg	  differentiation.	  To	  this	  end,	  we	  determined	  that	  vitamin	  D	  has	  a	  positive	  effect	  on	  human	  Treg	  differentiation	  and	  we	  identified	  a	  monocyte	  cell	  surface	  molecule	  that	  we	  believe	  may	  be	  important	  in	  promoting	  Treg	  differentiation	  namely,	  NRP-­‐1.	  	  NRP-­‐1	  is	  a	  multi-­‐functional	  transmembrane	  glycoprotein	  expressed	  on	  neuronal	  and	  endothelial	  cells	  as	  well	  as	  other	  cell	  types	  [37].	  NRP-­‐1	  binds	  vascular	  endothelial	  growth	  factor	  (VEGF)	  as	  well	  as	  other	  growth	  factors,	  class	  3	  semaphorins,	  and	  TGF-­‐β	  (both	  the	  active	  form	  and	  the	  LAP/	  latent	  TGF-­‐β	  complex).	  
	   	   	   	  
	  
8	  Consequently,	  NRP-­‐1	  plays	  an	  important	  role	  in	  angiogenesis,	  axon	  guidance	  and	  growth,	  cancer,	  and	  immunity.	  In	  cancer	  biology,	  NRP-­‐1	  overexpression	  has	  been	  shown	  to	  promote	  tumor	  growth	  and	  metastasis	  and	  is	  indicative	  of	  a	  poor	  prognosis.	  NRP-­‐1	  has	  also	  been	  associated	  with	  immune	  inhibition	  and	  is	  expressed	  on	  murine	  CD4+	  CD25+	  Tregs	  as	  well	  as	  some	  activated	  human	  Tregs	  [11,	  38,	  39].	  The	  effect	  of	  NRP-­‐1	  on	  cancer	  progression	  and	  immune	  inhibition	  is	  believed	  to	  correlate	  with	  the	  ability	  of	  NRP-­‐1	  to	  bind	  active	  and	  latent	  TGF-­‐β.	  As	  previously	  mentioned,	  NRP-­‐1	  is	  able	  to	  bind	  the	  LAP/latent	  TGF-­‐β	  complex	  and	  is	  suspected	  to	  activate	  TGF-­‐β	  although	  the	  mechanism	  remains	  unclear	  and	  investigators	  are	  currently	  searching	  for	  an	  additional	  receptor	  that	  could	  mediate	  this	  effect.	  In	  turn,	  TGF-­‐β	  is	  an	  important	  immunomodulatory	  cytokine	  that	  can	  promote	  tumor	  progression	  [11].	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CHAPTER TWO 
MATERIALS AND METHODS 
 
 
Human UCB Collection 
The nurses in the Birth Center at Gottlieb Memorial Hospital collected UCB samples in 
sterile BLOOD-PACK™ units (Fenwal, Inc., IL) that were anticoagulant treated. After 
collection, samples were transported to Loyola and processed as soon as possible.  
Adult Blood Collection 
Adult blood samples were collected in heparin coated tubes by Barb Sexton, RN, MS at 
Loyola University Medical Center following specific inclusion and exclusion criteria. 
Five vitamin D deficient and five vitamin D sufficient blood samples were collected for 
analysis where vitamin D deficiency was defined as less than 30ng/mL in accordance 
with clinically established parameters. Males and females age 18-80 with 25 OHD levels 
≤20ng/dl and able to give informed consent and comply with study procedures were 
included in the study. Age-matched samples were obtained. Individuals on 
glucocorticoids or immunosuppressants were excluded from the study as were individuals 
with evidence of active malignancies in the past 5 years, estimated GFR< 30 
mg/ml/min/1.73M2, alanine aminotransferase (ALT) >3x normal, congestive heart failure 
class 3 or 4, uncontrolled hyper/hypothyroidism, presence of an autoimmune disease, 
history of excessive alcohol consumption or drub abuse, or poor medical or psychiatric 
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risk for participation in clinical research in the opinion of the investigator. Women 
who were pregnant or nursing were also excluded from the study. 
Mononuclear Cell Isolation from Human UCB and Adult Peripheral Blood 
Blood was diluted with room temperature 1x PBS (1:1 ratio) and mononuclear cells were 
isolated by Ficoll Gradient Centrifugation using Lymphocyte Separation Medium 
(Cellgro). The buffy coat was carefully extracted by pipetting. For UCB, the 
centrifugation protocol was repeated twice to minimize red blood cell contamination. The 
mononuclear cells were then counted and prepared for downstream applications such as 
cell culture or flow cytometry. 
Human UCB Cell Culture 
Cells were cultured in RPMI 1640 Media (Thermo Scientific) supplemented with 10% 
FCS (Atlanta Biologicals), MEM essential and non-essential amino acids (Invitrogen), β-
mercaptoethanol (50 uM), sodium pyruvate (1mM), L-glutamine (2mM), penicillin (100 
I.U/mL) streptomycin (100 ug/ml), and HEPES (10 mM). Exogenous IL-2 (PeproTech) 
was added at 10ng/mL and soluble anti-CD3 (eBioscience) was added at 0.2ug/mL. Cells 
were cultured for up to 14 days and split approximately every two days. The 
concentration of IL-2 was maintained throughout. Where indicated, soluble 1,25-
dihydroxyvitamin D3 was added at 1.6, 3.1, 6.2, 12.5, or 25nM. For overnight culture of 
UCB, 1,25-dihydroxyvitamin D3 was added at 25nM and incubated for up to 24 hours 
without IL-2 and anti-CD3. 
Cell Enrichment and Co-culture 
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CD4+ T cells were enriched from whole UCB mononuclear cells via a total CD4+ BD 
IMag enrichment kit following the manufacturers protocol. For CD4+/THP1 cell co-
culture experiments, THP1 cells were irradiated at 3000 rad and then cultured with CD4+ 
T cells in a 3:1 ratio.  
Flow Cytometry  
Prior to staining, cells were blocked with purified human IgG (R&D Systems) for 5 
minutes in FACS buffer (1xPBS, 1% FCS, 0.1% sodium azide). Cells were then washed 
with FACS buffer and stained with the indicated mouse anti-human antibodies for 30 
minutes. Foxp3 (BD Pharmingen clone 259D/C7), CD4 (Biolegend clone RPA-T4), CD8 
(BD Pharmingen clone RPA-T8), CD25 (Biolegend clone BC96), CD36 (Biolegend 
clone 5-271), LAP (Biolegend clone TW4-2F8), CD14 (Biolegend clone HCD14), NRP-
1 (Biolegend clone 12C2). The following isotype controls were used: LAP (Biolegend 
clone MOPC-21), NRP-1 (BD Pharmingen clone G155-178), CD25 and CD36 
(Biolgengend clone MOPC-173), Foxp3 (Biolegend clone MOPC-21). For intracellular 
staining of the transcription factor Foxp3, a Foxp3 Fix/Perm buffer set (Biolegend) was 
used. Data were collected on FACS Canto II (Becton Dickinson) and ImageStreamX 
(Amnis Corp. Seattle, WA.) FlowJo software (Tree Star, Inc.) and Amnis Ideas 5.0 were 
used for data analysis. 
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CHAPTER	  THREE	  EXPERIMENTAL	  RESULTS	  	   We	  hypothesized	  that	  the	  immunomodulatory	  properties	  of	  vitamin	  D	  were	  a	  direct	  result	  of	  its	  ability	  to	  enhance	  human	  Treg	  differentiation.	  Our	  first	  goal	  was	  to	  determine	  if	  the	  serum	  concentration	  of	  vitamin	  D	  correlated	  with	  the	  Treg	  frequency	  in	  adult	  peripheral	  blood	  mononuclear	  cells	  (PBMC).	  Adult	  blood	  samples	  were	  collected	  by	  Barb	  Sexton,	  RN,	  MS	  at	  Loyola	  University	  Medical	  Center	  following	  specific	  inclusion	  and	  exclusion	  criteria.	  Males	  and	  females	  age	  18-­‐80	  were	  included	  in	  the	  study	  as	  long	  as	  they	  were	  able	  to	  give	  informed	  consent	  and	  comply	  with	  study	  procedures.	  In	  contrast,	  individuals	  on	  glucocorticoids	  and	  immunosuppressants	  were	  excluded	  from	  the	  study,	  as	  were	  individuals	  with	  evidence	  of	  autoimmune	  disease,	  hypo/hyperthyroidism,	  and	  history	  of	  excessive	  drug	  or	  alcohol	  consumption.	  Additionally,	  equal	  numbers	  of	  vitamin	  D	  sufficient	  and	  deficient	  blood	  samples	  were	  collected	  for	  analysis	  where	  vitamin	  D	  deficiency	  was	  defined	  as	  less	  than	  30ng/mL	  in	  accordance	  with	  clinically	  established	  parameters.	  Moreover,	  age-­‐matched	  samples	  were	  obtained.	  	  We	  expected	  that	  vitamin	  D	  sufficient	  individuals	  would	  have	  a	  higher	  peripheral	  blood	  Treg	  frequency	  as	  compared	  to	  vitamin	  D	  deficient	  individuals.	  PBMC’s	  were	  first	  isolated	  by	  Ficoll	  gradient	  separation	  using	  lymphocyte	  separation	  medium	  (Cellgro).	  The	  freshly	  isolated	  mononuclear	  cells	  were	  then	  prepared	  for	  flow	  cytometric	  analysis	  by	  staining	  for	  the	  Treg	  cell	  surface	  molecules	  CD4	  and	  CD25	  and	  the	  transcription	  factor	  Foxp3.	  Tregs	  were	  identified	  as	  being	  CD4+CD25+Foxp3+.	  Since	  blood	  was	  collected,	  processed,	  and	  stained	  on	  the	  same	  day,	  Treg	  frequency	  was	  reported	  at	  day	  0.	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  Figure	  1A	  depicts	  the	  Treg	  frequencies	  of	  vitamin	  D	  deficient	  (0-­‐30	  ng/mL)	  and	  sufficient	  (31-­‐100	  ng/mL)	  cohorts	  at	  day	  0.	  In	  figure	  1B	  the	  flow	  cytometry	  data	  were	  compiled	  to	  show	  the	  linear	  regression.	  In	  both	  plots	  the	  Treg	  frequency	  in	  adult	  PBMC	  was	  increased	  in	  vitamin	  D	  sufficient	  individuals	  as	  compared	  to	  deficient	  individuals,	  although	  the	  differences	  found	  by	  linear	  regression	  were	  not	  statistically	  significant.	  These	  results	  suggest	  that	  the	  serum	  concentration	  of	  vitamin	  D	  may	  be	  positively	  correlated	  with	  peripheral	  blood	  Treg	  frequency	  in	  adults.	  	  	  
 































































	   	   	  
	   	  
14	  effect	  of	  addition	  of	  vitamin	  D	  on	  Treg	  differentiation	  in	  whole	  UCB.	  Human	  UCB	  samples	  were	  obtained	  from	  Gottlieb	  Memorial	  Hospital	  and	  mononuclear	  cells	  were	  isolated	  by	  Ficoll	  gradient	  separation	  using	  lymphocyte	  separation	  medium	  (Cellgro).	  The	  freshly	  isolated	  mononuclear	  cells	  were	  then	  cultured	  for	  14	  days	  in	  medium	  supplemented	  with	  IL-­‐2	  and	  anti-­‐CD3	  with	  or	  without	  the	  addition	  of	  1,25-­‐dihydroxyvitamin	  D3.	  IL-­‐2	  is	  a	  T	  cell	  survival	  factor	  necessary	  for	  the	  growth,	  proliferation,	  and	  differentiation	  of	  Tregs	  and	  anti-­‐CD3	  simulates	  the	  T	  cell	  antigen	  receptor.	  Additionally,	  cells	  were	  cultured	  for	  14	  days	  because	  human	  T	  cells	  transiently	  express	  Foxp3	  after	  activation	  for	  approximately	  10	  days	  (Seki	  et	  al.,	  	  unpublished	  data).	  After	  14	  days	  of	  culture,	  cells	  were	  harvested	  and	  prepared	  for	  flow	  cytometric	  analysis	  by	  staining	  for	  the	  Treg	  cell	  surface	  molecules	  CD4	  and	  CD25	  and	  the	  transcription	  factor	  Foxp3.	  Tregs	  were	  identified	  as	  being	  CD4+CD25+Foxp3+.	  	  Figure	  2	  (A)	  depicts	  flow	  cytometry	  data	  of	  addition	  of	  1,25-­‐dihydroxyvitamin	  D3	  to	  whole	  UCB.	  Each	  panel	  shows	  CD25	  and	  Foxp3	  expression	  among	  total	  CD4+	  cells.	  Vitamin	  D	  supplementation	  to	  whole	  UCB	  resulted	  in	  a	  dose	  dependent	  increase	  in	  the	  Treg	  frequency.	  Moreover,	  the	  absolute	  number	  of	  Tregs	  was	  increased	  upon	  addition	  of	  vitamin	  D	  to	  whole	  UCB	  (Figure	  2	  B).	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* p < 0.05 by one way ANOVA with Dunnett's



























































	   	   	  
	   	  
16	  were	  harvested	  and	  prepared	  for	  flow	  cytometric	  analysis	  by	  staining	  for	  the	  Treg	  cell	  surface	  molecules	  CD4	  and	  CD25	  and	  the	  transcription	  factor	  Foxp3.	  	  Figure	  3	  depicts	  flow	  cytometry	  data	  of	  CD4+/	  THP1	  cell	  co-­‐culture	  stained	  at	  day	  14	  for	  Treg	  induction	  after	  addition	  of	  1,25-­‐dihydroxyvitamin	  D3.	  Tregs	  were	  identified	  as	  being	  CD4+CD25+Foxp3+	  and	  each	  panel	  depicts	  CD25	  and	  Foxp3	  expression	  among	  total	  CD4+	  cells.	  As	  hypothesized,	  there	  was	  a	  dose	  dependent	  increase	  in	  the	  Treg	  frequency	  from	  approximately	  24	  to	  53	  upon	  addition	  of	  1,25-­‐dihydroxyvitamin	  D3.	  Moreover,	  we	  obtained	  similar	  results	  in	  four	  independent	  experiments.	  	  	  
 
 To	  verify	  the	  effect	  of	  vitamin	  D	  on	  human	  Treg	  differentiation,	  we	  added	  a	  vitamin	  D	  receptor	  inhibitor	  to	  CD4+/	  THP1	  cell	  co-­‐culture.	  We	  hypothesized	  that	  addition	  of	  a	  vitamin	  D	  receptor	  inhibitor	  to	  CD4+/THP1	  cell	  co-­‐culture	  would	  result	  in	  a	  decrease	  in	  Treg	  differentiation.	  To	  test	  this	  hypothesis,	  human	  UCB	  CD4+	  T	  cells	  were	  cultured	  with	  irradiated	  THP1	  cells	  with	  or	  without	  the	  addition	  of	  the	  vitamin	  D	  receptor	  inhibitor	  ADMI3.	  After	  14	  days	  of	  culture,	  cells	  were	  



































	   	   	  
	   	  
17	  harvested	  and	  prepared	  for	  flow	  cytometric	  analysis	  by	  staining	  for	  the	  Treg	  cell	  surface	  molecules	  CD4	  and	  CD25	  and	  the	  transcription	  factor	  Foxp3.	  	  Figure	  4	  depicts	  flow	  cytometry	  data	  of	  CD4+/THP1	  cell	  co-­‐culture	  after	  addition	  of	  the	  vitamin	  D	  receptor	  inhibitor	  ADMI3.	  Each	  panel	  depicts	  CD25	  and	  Foxp3	  expression	  among	  total	  CD4+	  cells.	  When	  ADMI3	  was	  added	  at	  a	  concentration	  of	  ½	  IC50,	  the	  Treg	  frequency	  was	  decreased	  from	  approximately	  24	  to	  9.	  Since	  the	  ADMI3	  stock	  solution	  was	  suspended	  in	  ethanol,	  an	  ethanol	  control	  was	  included	  in	  the	  experiment,	  and	  showed	  no	  change	  in	  the	  Treg	  frequency.	  	  
	  	  To	  elucidate	  the	  mechanism	  by	  which	  vitamin	  D	  enhanced	  human	  Treg	  differentiation,	  we	  tested	  if	  vitamin	  D	  acted	  on	  monocytes	  and/or	  CD4+	  T	  cells.	  We	  expected	  that	  if	  vitamin	  D	  acted	  on	  monocytes	  to	  enhance	  Treg	  differentiation,	  there	  would	  be	  an	  increase	  in	  the	  Treg	  frequency	  when	  vitamin	  D	  pre-­‐treated	  THP1	  cells	  were	  cultured	  with	  untreated	  CD4+	  T	  cells.	  On	  the	  other	  hand,	  if	  vitamin	  D	  acted	  on	  CD4+	  T	  cells	  to	  enhance	  Treg	  differentiation,	  then	  we	  would	  expect	  to	  see	  an	  




























	   	   	  
	   	  
18	  increase	  in	  the	  Treg	  frequency	  when	  vitamin	  D	  pre-­‐treated	  CD4+	  T	  cells	  were	  cultured	  with	  untreated	  THP1	  cells.	  	  To	  test	  this,	  UCB	  CD4+	  T	  cells	  or	  THP1	  cells	  were	  incubated	  overnight	  with	  1,25-­‐dihydroxyvitamin	  D3.	  The	  next	  day	  cells	  were	  washed	  twice	  in	  medium	  and	  THP1	  cells	  were	  irradiated.	  Vitamin	  D	  pre-­‐treated	  CD4+	  T	  cells	  were	  then	  cultured	  with	  untreated	  THP1	  cells.	  Additionally,	  vitamin	  D	  pre-­‐treated	  THP1	  cells	  were	  cultured	  with	  untreated	  CD4+	  T	  cells.	  A	  control	  sample	  was	  also	  included	  in	  which	  untreated	  THP1	  cells	  were	  cultured	  with	  untreated	  CD4+	  T	  cells.	  Cells	  were	  cultured	  for	  14	  days	  in	  the	  presence	  of	  IL-­‐2	  and	  anti-­‐CD3	  and	  analyzed	  by	  flow	  cytometry	  for	  the	  expression	  of	  CD4,	  CD25,	  and	  the	  transcription	  factor	  Foxp3.	  	  Figure	  5	  depicts	  flow	  cytometry	  data	  of	  CD4+/THP1	  cell	  co-­‐culture	  where	  either	  THP1	  cells	  or	  CD4+	  T	  cells	  were	  incubated	  overnight	  with	  vitamin	  D	  before	  co-­‐culture.	  When	  vitamin	  D	  pre-­‐treated	  THP1	  cells	  were	  cultured	  with	  untreated	  CD4+	  T	  cells,	  the	  Treg	  frequency	  was	  increased	  from	  approximately	  34	  to	  49.	  In	  contrast,	  when	  vitamin	  D	  pre-­‐treated	  CD4+	  T	  cells	  were	  cultured	  with	  untreated	  THP1	  cells,	  there	  was	  no	  change	  in	  the	  Treg	  frequency	  as	  compared	  to	  no	  treatment.	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   Based	  on	  these	  data,	  we	  hypothesized	  that	  vitamin	  D	  enhanced	  human	  Treg	  differentiation	  by	  acting	  on	  monocytes	  to	  alter	  the	  expression	  of	  LAP	  and/or	  NRP-­‐1.	  To	  test	  this	  hypothesis,	  we	  determined	  if	  addition	  of	  vitamin	  D	  altered	  the	  expression	  of	  NRP-­‐1	  and	  LAP.	  Freshly	  isolated	  UCB	  mononuclear	  cells	  were	  incubated	  overnight	  with	  or	  without	  the	  addition	  of	  1,25-­‐dihyrdoxyvitamin	  D3.	  The	  next	  day	  cells	  were	  harvested	  and	  prepared	  for	  flow	  cytometric	  analysis	  by	  staining	  for	  the	  monocyte	  cell	  surface	  molecules	  CD36,	  NRP-­‐1,	  and	  LAP.	  	  Figure	  7	  (A)	  depicts	  flow	  cytometry	  data	  of	  expression	  of	  CD36	  and	  NRP-­‐1	  in	  whole	  UCB.	  Each	  panel	  shows	  CD36	  and	  NRP-­‐1	  expression	  among	  total	  live	  cells.	  In	  both	  vitamin	  D	  treated	  and	  untreated	  UCB	  there	  was	  a	  CD36hi	  population.	  Under	  untreated	  conditions,	  14%	  of	  the	  CD36hi	  population	  expressed	  NRP-­‐1.	  When	  cells	  were	  treated	  with	  vitamin	  D,	  the	  frequency	  of	  the	  CD36hi	  NRP-­‐1	  positive	  population	  increased	  to	  31%.	  Moreover,	  the	  CD36hi	  NRP-­‐1	  positive	  population	  became	  brighter	  as	  shown	  in	  panel	  B.	  After	  addition	  of	  vitamin	  D	  the	  expression	  of	  NRP-­‐1	  increased	  and	  the	  MFI	  increased	  from	  approximately	  300	  to	  approximately	  1500.	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Bright Detail Similarity R3_MC_Ch03
Population Count %Gated Median
 36+ NRP-1+ & singlets & focus  280  100  0.8751
 R2 & 36+ NRP-1+ & singlets & focus  19  6.79  1.527
36+ NRP-1+  
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Bright Detail Similarity R3_MC_Ch03
Population Count %Gated Median
 36+ NRP-1+ & singlets & focus  151  1 0  1.258
 R2 & 36+ NRP-1+ & singlets & focus  63  41.7  1.831
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We	  performed	  the	  same	  analysis	  for	  co-­‐localization	  between	  CD14	  and	  NRP-­‐1	  (Figure	  12).	  The	  merged	  image	  analysis	  shows	  co-­‐localization	  between	  CD14	  and	  NRP-­‐1	  in	  vitamin	  D	  treated	  UCB.	  In	  contrast,	  there	  was	  no	  co-­‐localization	  between	  CD14	  and	  NRP-­‐1	  in	  untreated	  UCB.	  Panel	  B	  indicates	  histogram	  analysis	  of	  co-­‐localization	  between	  CD14	  and	  NRP-­‐1	  with	  or	  without	  the	  addition	  of	  vitamin	  D.	  Each	  histogram	  depicts	  co-­‐localization	  among	  CD14+NRP-­‐1+	  cells.	  In	  untreated	  UCB	  CD14	  was	  co-­‐localized	  with	  NRP-­‐1	  on	  3%	  of	  the	  cells.	  After	  vitamin	  D	  treatment	  CD14	  and	  NRP-­‐1	  were	  co-­‐localized	  on	  75%	  of	  the	  cells.	  Additionally,	  the	  median	  values	  were	  very	  similar	  in	  vitamin	  D	  treated	  and	  untreated	  UCB,	  indicating	  that	  there	  was	  no	  change	  in	  the	  relative	  number	  of	  complexes	  of	  CD14	  and	  NRP-­‐1	  per	  cell	  after	  addition	  of	  vitamin	  D.	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Bright Detail Similarity R3_MC_Ch01
Population Count %Gated Median
 14+ nrp1+ & singlets & focus  77  100  1.036
 R3 & 14+ nrp1+ & singlets & focus  2  2.6  1.529
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Bright Detail Similarity R3_MC_Ch01
Population Count %Gated Median
 14+ nrp1+ & singlets & focus  144  100  1.814
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Bright Detail Similarity R3_MC_Ch01_Ch03
Population Count %Gated Median
 14+ 36+ & singlets & focus  119  100  1.568
 R1 & 14+ 6+ & singlets & focus  5  49.6  2.007
14+ 36+ 
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Bright Detail Similarity R3_MC_Ch01_Ch03
Population Count %Gated Median
 14+ 36+ & singlets & focus  166  100  1.657
 R1 & 14+ 36+ & singlets & focus  87  52.4  2.111
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W! #W%




Finally,	  we	  addressed	  the	  question	  if	  LAP	  was	  present	  in	  the	  complex	  with	  NRP-­‐1	  and/or	  CD14	  and	  CD36	  (Figure	  14).	  In	  both	  vitamin	  D	  treated	  and	  untreated	  UCB	  there	  was	  no	  co-­‐localization	  between	  LAP	  and	  NRP-­‐1	  detectable	  by	  the	  merged	  image	  analysis.	  Panel	  B	  shows	  histogram	  analysis	  of	  co-­‐localization	  between	  LAP	  and	  NRP-­‐1	  with	  or	  without	  the	  addition	  of	  vitamin	  D.	  Each	  histogram	  depicts	  co-­‐localization	  among	  LAP+NRP-­‐1+	  cells.	  In	  both	  vitamin	  D	  treated	  and	  untreated	  UCB	  there	  was	  no	  co-­‐localization	  detectable	  between	  LAP	  and	  NRP-­‐1.	  Additionally,	  the	  median	  values	  were	  very	  similar.	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Bright Detail Similarity R3_MC_Ch02
Population Count %Gated Median
 LAP+ NRP1+ & singlets & focus  153  100  1.346
 R6 & LAP+ NRP1+ & singlets & focus  0  0  NaN
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Bright Detail Similarity R3_MC_Ch02
Population Count %Gated Median
 LAP+ NRP1+ & singlets & focus  32  100  1.517
 R6 & LAP+ NRP1+ & singlets & focus  2  0.62  2.428
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Bright Detail Similarity R3_MC_Ch02
Population Count %Gated Median
 36+ LAP+ & singlets & focus  452  100  0.8466
 R5 & 36+ LAP+ & singlets & focus  2  0.44  2.321
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Bright Detail Similarity R3_MC_Ch02
Population Count %Gated Median
 36+ LAP+ & singlets & focus  186  100  0.9277
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Bright Detail Similarity R3_MC_Ch02
Population Count %Gated Median
 14+ LAP+ & singlets & focus  130  100  0.9469
 R4 & 14+ LAP+ & singlets & focus  0  0  NaN
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Bright Detail Similarity R3_MC_Ch02
Population Count %Gated Median
 14+ LAP+ & singlets & focus  168  100  1.286
 R4 & 14+ LAP+ & singlets & focus  0  0  NaN
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CHAPTER	  FOUR	  DISCUSSION	  	   Vitamin	  D	  is	  considered	  to	  be	  an	  immunomodulatory	  molecule	  with	  important	  implications	  in	  autoimmunity	  and	  transplantation	  [2,	  10].	  The	  exact	  mechanisms	  underlying	  the	  anti-­‐inflammatory	  and	  immunosuppressive	  properties	  of	  vitamin	  D	  are	  not	  fully	  understood,	  however.	  Many	  clinicians	  and	  researchers	  have	  questioned	  whether	  or	  not	  vitamin	  D	  supplementation	  may	  be	  an	  effective	  form	  of	  treatment	  for	  individuals	  with	  autoimmune	  disease	  and	  graft	  vs.	  host	  disease	  (GVHD).	  Indeed,	  numerous	  clinical	  research	  studies	  have	  focused	  on	  vitamin	  D	  supplementation	  as	  a	  way	  to	  suppress	  the	  immune	  response	  and	  prevent	  graft	  rejection	  in	  transplant	  patients.	  For	  example,	  vitamin	  D	  supplementation	  has	  been	  shown	  to	  slow	  the	  loss	  of	  renal-­‐allograft	  function	  in	  kidney	  transplant	  patients	  [9].	  Additionally,	  various	  clinical	  trials	  have	  investigated	  the	  merits	  of	  vitamin	  D	  supplementation	  in	  M.S	  patients	  as	  a	  way	  to	  decrease	  inflammation,	  slow	  disease	  progression,	  and	  improve	  the	  overall	  quality	  of	  life	  in	  these	  patients	  [42].	  To	  this	  end,	  it’s	  been	  reported	  that	  vitamin	  D	  supplementation	  at	  certain	  concentrations	  decreased	  the	  incidence	  of	  disease	  relapse	  in	  M.S	  patients.	  In	  contrast,	  some	  studies	  showed	  that	  vitamin	  D	  had	  no	  effect	  on	  the	  disease	  progression	  of	  M.S	  [42].	  There	  are	  more	  clinical	  trials	  currently	  underway	  to	  help	  evaluate	  the	  potential	  of	  vitamin	  D	  supplementation	  as	  a	  therapeutic	  for	  autoimmune	  diseases	  such	  as	  M.S	  [43].	  In	  order	  to	  explain	  either	  the	  success	  or	  failure	  of	  such	  clinical	  trials,	  it	  will	  be	  beneficial	  to	  have	  a	  greater	  understanding	  of	  the	  mechanisms	  by	  which	  vitamin	  D	  exerts	  its	  immunomodulatory	  effects.	  	  Our	  data	  predict	  that	  vitamin	  D	  regulates	  immune	  responses	  by	  enhancing	  human	  Treg	  differentiation.	  First,	  we	  found	  a	  potential	  positive	  correlation	  between	  
	  	  
33	  
the	  serum	  concentration	  of	  vitamin	  D	  and	  the	  Treg	  frequency	  in	  adult	  peripheral	  blood.	  Additionally,	  we	  found	  that	  vitamin	  D	  supplementation	  to	  whole	  UCB	  as	  well	  as	  CD4+/THP1	  cell	  co-­‐culture	  boosted	  Treg	  differentiation.	  Taken	  together,	  these	  data	  suggest	  that	  the	  reason	  vitamin	  D	  may	  be	  an	  effective	  form	  of	  treatment	  for	  autoimmune	  disease	  and	  GVHD	  is	  because	  vitamin	  D	  enhances	  human	  Treg	  differentiation,	  thereby	  promoting	  an	  anti-­‐inflammatory	  and	  regulatory	  environment.	  In	  the	  future,	  we	  plan	  on	  supplementing	  adult	  blood	  cultures	  with	  vitamin	  D	  to	  test	  if	  we	  can	  also	  boost	  the	  Treg	  frequency	  in	  adults.	  We	  are	  currently	  collecting	  equal	  numbers	  of	  vitamin	  D	  sufficient	  and	  deficient	  blood	  samples.	  Our	  data	  demonstrate	  that	  vitamin	  D	  deficient	  individuals	  have	  a	  lower	  peripheral	  blood	  Treg	  frequency	  as	  compared	  to	  vitamin	  D	  sufficient	  individuals.	  We	  hypothesize	  that	  addition	  of	  vitamin	  D	  to	  deficient	  adult	  blood	  cultures	  will	  increase	  the	  Treg	  frequency.	  As	  previously	  mentioned,	  there	  appears	  to	  be	  a	  positive	  correlation	  between	  the	  serum	  concentration	  of	  vitamin	  D	  and	  the	  Treg	  frequency	  in	  adult	  peripheral	  blood	  (Figure	  1).	  Noticeably,	  there	  was	  a	  discrepancy	  in	  the	  p-­‐value	  when	  the	  data	  were	  presented	  by	  grouping	  analysis	  (Figure	  1A)	  or	  as	  a	  linear	  regression	  plot	  (Figure	  1B).	  The	  p-­‐value	  was	  0.01	  when	  the	  data	  were	  presented	  by	  grouping	  analysis	  as	  compared	  to	  0.07	  in	  the	  linear	  regression	  plot.	  It’s	  possible	  that	  the	  small	  sample	  size	  of	  our	  study	  contributed	  to	  this	  discrepancy	  since	  we	  only	  had	  10	  patients	  enrolled	  in	  the	  study.	  We	  are	  currently	  repeating	  this	  experiment	  to	  confirm	  our	  results	  and	  double	  our	  sample	  size.	  Importantly,	  even	  though	  the	  p-­‐value	  was	  slightly	  different,	  we	  still	  saw	  the	  same	  trend	  in	  the	  data	  where	  vitamin	  D	  sufficient	  individuals	  had	  a	  higher	  Treg	  frequency	  as	  compared	  to	  vitamin	  D	  deficient	  individuals.	  	  In	  the	  human	  body,	  the	  main	  circulating	  form	  of	  vitamin	  D	  is	  25-­‐hydroxyvitamin	  D3	  [3,	  4].	  We	  added	  the	  active	  form	  of	  vitamin	  D,	  1,25-­‐dihyrodxyvitamin	  D3	  to	  cultures	  of	  whole	  UCB	  as	  well	  as	  CD4+/THP1	  cell	  co-­‐culture	  to	  enhance	  Treg	  differentiation.	  Importantly,	  the	  vitamin	  D	  activating	  enzyme,	  1-­‐α	  hydroxylase	  (CYP27B1)	  is	  expressed	  by	  a	  variety	  of	  extrarenal	  tissues	  including	  immune	  cells	  such	  as	  monocytes,	  DC’s,	  and	  T	  cells	  [44,	  45].	  Vitamin	  D	  activation	  in
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  the	  kidney	  is	  important	  to	  maintain	  bone	  health	  and	  regulate	  calcium	  metabolism,	  but	  researchers	  suspect	  that	  vitamin	  D	  activation	  in	  extrarenal	  tissues	  such	  as	  immune	  cells	  may	  have	  other	  important	  biological	  effects	  [46].	  Indeed,	  vitamin	  D	  activation	  in	  DC’s	  has	  been	  shown	  to	  modulate	  T	  cell	  responses,	  thereby	  regulating	  the	  inflammatory	  response	  [45].	  In	  preliminary	  data	  not	  shown	  here,	  we	  determined	  that	  human	  UCB	  monocytes	  expressed	  the	  enzyme	  CYP27B1	  and	  are	  therefore	  capable	  of	  activating	  25-­‐hydroxyvitamin	  D3	  to	  1,25-­‐dihydroxyvitamin	  D3.	  Moreover,	  there	  are	  low	  levels	  of	  25-­‐hydroxyvitmain	  D3	  in	  our	  RPMI	  culture	  media	  that	  could	  mediate	  vitamin	  D	  activation	  in	  our	  culture	  system.	  We	  found	  that	  addition	  of	  exogenous,	  active	  vitamin	  D	  enhanced	  Treg	  differentiation	  in	  our	  culture	  system.	  Additionally,	  our	  data	  suggest	  that	  vitamin	  D	  enhances	  Treg	  differentiation	  by	  acting	  on	  monocytes	  to	  increase	  the	  expression	  of	  the	  monocyte	  cell	  surface	  molecules	  NRP-­‐1	  and	  LAP,	  and	  by	  promoting	  co-­‐localization	  between	  CD36	  and	  NRP-­‐1	  as	  well	  as	  between	  NRP-­‐1	  and	  CD14.	  The	  effect	  of	  vitamin	  D	  on	  the	  co-­‐localization	  between	  these	  molecules	  may	  be	  functionally	  important	  for	  the	  activation	  of	  TGF-­‐β	  and	  therefore	  the	  differentiation	  of	  Tregs	  in	  our	  culture	  system.	  	  First,	  co-­‐localization	  between	  CD36	  and	  NRP-­‐1	  may	  promote	  TGF-­‐β	  activation	  and	  enhance	  Treg	  differentiation.	  As	  previously	  mentioned,	  NRP-­‐1	  is	  a	  multifunctional	  protein	  capable	  of	  binding	  TGF-­‐β	  at	  the	  cell	  surface.	  Moreover,	  researchers	  suspect	  that	  NRP-­‐1	  may	  interact	  with	  an	  unidentified	  receptor	  to	  activate	  latent	  TGF-­‐β	  and	  inhibit	  the	  immune	  response	  [11].	  CD36	  is	  an	  integral	  membrane	  protein	  and	  scavenger	  receptor	  that	  is	  involved	  in	  several	  important	  physiological	  processes	  such	  as	  angiogenesis.	  Moreover,	  CD36	  binds	  several	  different	  classes	  of	  ligands	  including	  TSP-­‐1	  [47].	  In	  turn,	  TSP-­‐1	  is	  a	  matricellular	  glycoprotein	  that	  interacts	  with	  the	  LAP/latent	  TGF-­‐β	  complex	  to	  activate	  TGF-­‐β,	  thereby	  modulating	  immune	  responses	  [48].	  We	  propose	  that	  NRP-­‐1	  interacts	  with	  the	  CD36/TSP-­‐1	  complex	  to	  facilitate	  the	  activation	  of	  TGF-­‐β	  and	  enhance	  Treg	  differentiation	  in	  response	  to	  vitamin	  D.	  We	  also	  demonstrated	  that	  vitamin	  D	  promoted	  co-­‐localization	  between	  CD14	  and	  NRP-­‐1.	  CD14	  is	  a	  cell	  surface	  molecule	  that	  functions	  as	  a	  co-­‐receptor	  with	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TLR-­‐4	  for	  LPS.	  LPS	  is	  a	  pathogen	  associated	  molecular	  pattern	  (PAMP)	  found	  on	  the	  outer	  membrane	  of	  gram	  negative	  bacteria	  that	  stimulates	  inflammation	  and	  activation	  of	  the	  innate	  immune	  response.	  Moreover,	  preliminary	  studies	  in	  our	  lab	  have	  shown	  that	  LPS	  addition	  to	  human	  UCB	  results	  in	  a	  decrease	  in	  Treg	  differentiation.	  We	  hypothesize	  that	  NRP-­‐1	  and	  CD14	  form	  a	  complex	  at	  the	  cell	  surface	  that	  is	  regulated	  by	  LPS	  such	  that	  in	  the	  presence	  of	  LPS,	  NRP-­‐1	  is	  down	  regulated	  and	  Treg	  induction	  is	  prohibited.	  In	  contrast,	  when	  LPS	  is	  absent	  NRP-­‐1	  would	  be	  up	  regulated	  and	  Treg	  induction	  enhanced.	  We	  are	  currently	  working	  to	  determine	  the	  effect	  of	  LPS	  addition	  on	  NRP-­‐1	  expression.	  We	  plan	  to	  add	  soluble	  LPS	  to	  UCB	  for	  up	  to	  24	  hours	  and	  assess	  the	  level	  of	  NRP-­‐1	  expression	  by	  flow	  cytometry.	  We	  would	  expect	  to	  see	  decreased	  levels	  of	  NRP-­‐1	  upon	  LPS	  addition.	  	   We	  were	  surprised	  to	  find	  that	  there	  was	  no	  co-­‐localization	  detectable	  between	  LAP	  and	  NRP-­‐1	  because	  it’s	  been	  documented	  that	  NRP-­‐1	  can	  bind	  to	  the	  LAP/latent	  TGF-­‐β	  complex	  [11].	  It’s	  possible	  we	  were	  unable	  to	  detect	  co-­‐localization	  between	  NRP-­‐1	  and	  LAP	  because	  our	  flow	  antibodies	  created	  steric	  hindrance	  that	  occluded	  this	  interaction.	  Additionally,	  we	  found	  that	  LAP	  is	  generally	  hard	  to	  detect	  by	  flow	  cytometry.	  As	  previously	  shown,	  the	  frequency	  of	  CD36hi	  LAP+	  cells	  in	  untreated	  UCB	  was	  approximately	  4%.	  One	  possibility	  for	  why	  LAP	  was	  hard	  to	  detect	  at	  the	  cell	  surface	  is	  that	  LAP	  was	  rapidly	  internalized	  or	  removed	  by	  TSP-­‐1	  after	  delivering	  TGF-­‐β	  to	  the	  NRP-­‐1	  complex.	  This	  could	  also	  explain	  why	  we	  were	  unable	  to	  detect	  co-­‐localization	  between	  CD36	  and	  LAP	  or	  CD14	  and	  LAP.	  Interestingly,	  Glinka	  and	  colleagues	  determined	  that	  NRP-­‐1	  and	  LAP	  co-­‐localized	  on	  the	  membrane	  of	  MDA-­‐MB-­‐231	  cells	  (a	  human	  breast	  adenocarcinoma	  cell	  line)	  and	  they	  showed	  that	  the	  complex	  was	  internalized	  within	  minutes	  [49].	  Additionally,	  it’s	  been	  suggested	  that	  NRP-­‐1	  may	  not	  be	  the	  primary	  receptor	  for	  LAP.	  Researchers	  have	  found	  that	  LAP	  has	  an	  RGD	  integrin	  binding	  site	  and	  LAP	  can	  bind	  other	  receptors	  at	  the	  cell	  surface	  including	  the	  molecule	  GARP	  [11].	  Moreover,	  it’s	  previously	  been	  shown	  in	  our	  lab	  that	  UCB	  CD14+CD36hi	  monocytes	  express	  GARP	  (Jaeger,	  under	  revision).	  It’s	  therefore	  possible	  that	  LAP	  binds	  to	  some	  other	  molecule	  such	  as	  GARP	  at	  the	  cell	  surface	  to	  deliver	  TGF-­‐β	  to	  the	  NRP-­‐1	  complex	  in	  our	  culture	  system.
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Cancer	  cells	  frequently	  express	  NRP-­‐1	  and	  RGD	  binding	  integrins	  [49].	  NRP-­‐1	  expression	  by	  cancer	  cells	  has	  also	  been	  linked	  to	  tumor	  metastasis	  and	  is	  indicative	  of	  a	  poor	  prognosis	  [49,	  50].	  Parikh	  et	  al.	  studied	  the	  relationship	  between	  colon	  cancer	  and	  NRP-­‐1	  expression	  using	  human	  colon	  adenocarcinoma	  tissue	  specimens.	  NRP-­‐1	  was	  expressed	  in	  all	  adenocarcinoma	  tissue	  specimens	  collected.	  In	  contrast,	  NRP-­‐1	  was	  not	  expressed	  in	  colon	  samples	  taken	  from	  the	  adjacent	  nonmalignant	  tissue.	  Furthermore,	  Parikh	  and	  colleagues	  found	  that	  over	  expression	  of	  NRP-­‐1	  in	  KM12SM/LM2 cells	  	  (human	  colon	  cancer	  cells)	  promoted	  an	  increase	  in	  tumor	  growth	  [51].	  NRP-­‐1	  expression	  has	  also	  been	  implicated	  in	  a	  number	  of	  other	  cancers	  including	  breast,	  prostate,	  lung,	  and	  pancreatic	  cancer	  [52].	  In	  many	  cases	  the	  functional	  role	  of	  NRP-­‐1	  in	  promoting	  tumor	  survival	  and	  growth	  remains	  unclear.	  Researchers	  have	  demonstrated	  that	  NRP-­‐1	  expression	  by	  breast	  cancer	  cells	  facilitated	  tumor	  survival	  by	  inhibiting	  hypoxia-­‐induced	  apoptosis	  [52].	  Researchers	  suspect	  another	  way	  NRP-­‐1	  may	  function	  to	  aid	  tumor	  progression	  is	  by	  activating	  TGF-­‐β	  at	  the	  cancer	  cell	  membrane	  [49].	  Glinka	  and	  colleagues	  studied	  the	  ability	  of	  NRP-­‐1	  to	  activate	  TGF-­‐β	  at	  the	  cell	  surface	  using	  a	  breast	  cancer	  cell	  line.	  They	  determined	  that	  NRP-­‐1	  could	  activate	  LAP/	  TGF-­‐β	  after	  the	  latent	  complex	  had	  attached	  to	  an	  αvβ3	  integrin	  or	  GARP	  at	  the	  cell	  surface.	  They	  also	  demonstrated	  that	  NRP-­‐1	  bound	  TGF-­‐β	  receptors	  at	  the	  cell	  surface,	  including	  the	  TβRI	  and	  TβRII	  receptors.	  TβRI	  and	  TβRII	  normally	  form	  a	  complex	  with	  TGF-­‐β	  at	  the	  cell	  surface,	  signaling	  through	  SMAD’s	  to	  activate	  cellular	  transcription.	  NRP-­‐1	  was	  found	  to	  be	  co-­‐localized	  with	  TβRI	  at	  the	  cell	  membrane	  of	  breast	  cancer	  cells.	  Additionally,	  TβRI,	  TβRII,	  and	  NRP-­‐1	  were	  co-­‐internalized	  upon	  addition	  of	  TGF-­‐β.	  Knockdown	  of	  NRP-­‐1	  in	  breast	  cancer	  cells	  has	  also	  been	  shown	  to	  greatly	  reduce	  TGF-­‐β	  signaling.	  These	  data	  suggest	  that	  NRP-­‐1	  can	  bind	  and	  activate	  TGF-­‐β	  as	  well	  as	  augment	  TGF-­‐β	  signaling	  in	  cancer	  cells	  [49].	  	  In	  addition	  to	  cancer,	  NRP-­‐1	  may	  also	  play	  a	  role	  in	  autoimmunity.	  MS	  is	  a	  progressive	  inflammatory	  disease	  affecting	  the	  central	  nervous	  system	  (CNS).	  The	  underlying	  cause	  of	  MS	  in	  humans	  is	  still	  relatively	  unclear.	  It’s	  been	  demonstrated	  that	  antigen	  specific	  CD4+	  T	  cells	  migrate	  to	  the	  CNS	  and	  destroy	  the	  myelin	  sheath	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of	  nerves	  in	  EAE,	  a	  mouse	  model	  of	  MS.	  The	  inflammation	  and	  destruction	  of	  myelin	  caused	  by	  CD4+	  T	  cells	  results	  in	  a	  decline	  of	  motor	  function	  culminating	  in	  paralysis	  [53].	  As	  previously	  mentioned,	  NRP-­‐1	  is	  expressed	  on	  mouse	  CD4+CD25+	  Treg	  cells	  and	  by	  some	  activated	  human	  Tregs	  [11,	  38,	  39].	  Solomon	  et	  al.	  demonstrated	  that	  overexpression	  of	  NRP-­‐1	  in	  mouse	  CD4+	  T	  cells	  correlated	  with	  a	  decrease	  in	  the	  disease	  progression	  of	  EAE.	  Additionally,	  NRP-­‐1	  knockout	  mice	  developed	  more	  severe	  disease	  [53].	  NRP-­‐1	  expression	  has	  also	  been	  studied	  in	  the	  context	  of	  the	  autoimmune	  disease	  IBD.	  Murine	  CD4+CD25+	  Treg	  cells	  expressing	  Foxp3	  and	  NRP-­‐1	  have	  been	  identified	  as	  a	  critical	  T	  cell	  subset	  in	  the	  regulation	  of	  the	  aberrant	  gut	  inflammatory	  response	  characteristic	  of	  IBD	  [54].	  These	  data	  indicate	  that	  NRP-­‐1	  may	  play	  an	  important	  role	  in	  regulating	  the	  immune	  response	  and	  protecting	  against	  the	  development	  of	  various	  autoimmune	  diseases.	  The	  link	  between	  vitamin	  D	  and	  cancer	  risk	  is	  still	  poorly	  understood.	  One	  hypothesis	  is	  that	  the	  anti-­‐proliferative	  effects	  of	  vitamin	  D	  are	  protective	  against	  tumor	  development	  and	  progression	  [55].	  In	  fact,	  epidemiological	  studies	  indicate	  that	  vitamin	  D	  levels	  inversely	  correlate	  with	  the	  development	  and/or	  fatality	  of	  breast	  cancer	  [56].	  Additionally,	  there	  are	  reports	  indicating	  that	  certain	  VDR	  polymorphisms	  are	  associated	  with	  an	  increased	  risk	  in	  the	  development	  of	  breast	  cancer	  [55,	  57].	  The	  FokI	  single	  nucleotide	  polymorphism	  in	  the	  VDR	  correlates	  with	  decreased	  transcriptional	  activation	  of	  the	  VDR.	  McKay	  et	  al.	  found	  that	  the	  FokI	  polymorphism	  was	  associated	  with	  an	  increased	  risk	  in	  the	  development	  of	  breast	  cancer	  [55].	  In	  contrast,	  Bretherton-­‐Watt	  and	  colleagues	  determined	  that	  there	  was	  no	  correlation	  between	  the	  FokI	  polymorphism	  and	  breast	  cancer	  risk	  in	  Caucasian	  women	  from	  the	  United	  Kingdom	  [58].	  Admittedly,	  there	  are	  many	  discrepancies	  in	  the	  literature	  regarding	  the	  link	  between	  particular	  VDR	  polymorphisms	  and	  breast	  cancer	  risk.	  As	  a	  caveat	  to	  these	  findings,	  it’s	  understood	  that	  allelic	  frequencies	  of	  VDR	  polymorphisms	  vary	  by	  ethnicity.	  It’s	  possible	  that	  the	  link	  between	  vitamin	  D	  levels	  and	  cancer	  may	  differ	  depending	  on	  sex,	  ethnicity,	  or	  other	  factors.	  Researchers	  have	  also	  investigated	  a	  potential	  link	  between	  cancer	  and	  the	  expression	  of	  the	  vitamin	  D	  activating	  and	  catabolizing	  enzymes,	  CYP27B1	  and	  CYP24A1	  respectively.	  As	  previously	  mentioned,	  the	  enzyme	  CYP27B1	  converts	  25-­‐
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hydroxyvitamin	  D3	  to	  1,25-­‐dihydroxyvitamin	  D3,	  the	  biologically	  active	  form	  of	  vitamin	  D.	  Vitamin	  D	  activation	  is	  regulated	  by	  the	  enzyme	  CYP24A1,	  which	  functions	  to	  inactivate	  1,25-­‐dihydroxyvitamin	  D3.	  CYP27B1	  and	  CYP24A1	  are	  both	  expressed	  in	  the	  kidney	  as	  well	  as	  by	  a	  variety	  of	  other	  cell	  types	  including	  immune	  cells	  and	  cancer	  cells	  [59].	  Overexpression	  of	  CYP24A1	  has	  been	  associated	  with	  colorectal	  cancer	  [60].	  Expression	  of	  CYP27B1	  and	  CYP24A1	  has	  also	  been	  studied	  in	  the	  context	  of	  breast	  cancer.	  Townsend	  et	  al.	  compared	  the	  RNA	  levels	  of	  CYP27B1,	  the	  VDR,	  and	  CYP24A1	  in	  normal	  breast	  tissue	  and	  cancerous	  breast	  tissue	  among	  Caucasian	  females.	  Expression	  of	  CYP27B1,	  the	  VDR,	  and	  CYP24A1	  were	  all	  up-­‐regulated	  in	  breast	  cancer	  tissue	  as	  compared	  to	  normal	  breast	  tissue.	  Furthermore,	  both	  CYP27B1	  and	  CYP24A1	  were	  shown	  to	  be	  functionally	  active	  in	  the	  normal	  and	  cancerous	  tissues	  [59].	  Admittedly,	  the	  up-­‐regulation	  of	  both	  the	  vitamin	  D	  activating	  and	  catabolizing	  enzymes	  in	  breast	  cancer	  cells	  as	  reported	  by	  Townsend	  et	  al.	  makes	  it	  difficult	  to	  conclude	  that	  vitamin	  D	  has	  a	  protective	  effect	  against	  breast	  cancer.	  Others	  have	  reported	  that	  there	  are	  multiple	  VDR	  binding	  sites	  within	  the	  promoter	  of	  the	  CYP24A1	  gene,	  and	  the	  number	  of	  VDR	  binding	  sites	  was	  increased	  in	  malignant	  mammary	  cells	  as	  compared	  to	  normal	  mammary	  cells.	  These	  results	  suggest	  that	  the	  catabolism	  of	  vitamin	  D	  may	  be	  increased	  selectively	  in	  cancerous	  cells	  to	  promote	  disease	  progression	  [61].	  Interestingly,	  our	  data	  suggest	  that	  high	  levels	  of	  vitamin	  D	  may	  increase	  the	  risk	  of	  cancer.	  We	  demonstrated	  that	  vitamin	  D	  increased	  the	  expression	  of	  NRP-­‐1	  in	  human	  UCB.	  Moreover,	  NRP-­‐1	  expression	  by	  cancer	  cells	  is	  associated	  with	  increased	  tumor	  growth	  and	  metastasis	  [49].	  If	  vitamin	  D	  increased	  the	  expression	  of	  NRP-­‐1	  in	  cancer	  cells,	  then	  high	  levels	  of	  vitamin	  D	  could	  contribute	  to	  increased	  tumor	  growth	  and	  metastasis.	  It’s	  possible	  that	  the	  effect	  of	  vitamin	  D	  on	  the	  expression	  of	  NRP-­‐1	  in	  adult	  cancer	  cells	  is	  different	  than	  in	  human	  UCB,	  however.	  In	  fact,	  we	  found	  that	  while	  vitamin	  D	  increased	  the	  expression	  of	  NRP-­‐1	  in	  human	  UCB,	  the	  effect	  of	  vitamin	  D	  on	  NRP-­‐1	  expression	  in	  THP1	  cells	  was	  not	  as	  strong	  Furthermore,	  the	  transcriptional	  and/or	  translational	  regulation	  of	  NRP-­‐1	  in	  cancer	  cells	  may	  be	  different	  than	  in	  healthy	  UCB	  mononuclear	  cells.	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Lastly,	  it’s	  still	  unknown	  whether	  vitamin	  D	  effects	  the	  expression	  of	  NRP-­‐1	  at	  the	  transcriptional	  level	  or	  the	  protein	  level	  in	  our	  culture	  system.	  Regulation	  of	  transcription	  of	  the	  NRP-­‐1	  gene	  is	  controlled,	  in	  part,	  by	  the	  CCAAT	  box	  upstream	  of	  the	  transcription	  start	  site	  [62,	  63].	  There	  are	  many	  CCAAT	  binding	  proteins	  that	  activate	  transcription.	  In	  mice,	  the	  transcription	  factor	  nuclear	  factor	  Y	  (NF-­‐Y)	  is	  an	  important	  CCAAT	  binding	  protein	  that	  activates	  transcription	  of	  various	  genes.	  The	  VDR	  is	  also	  known	  to	  promote	  activation	  of	  certain	  genes	  with	  a	  CCAAT	  box	  in	  the	  promoter	  region.	  NF-­‐Y	  and	  the	  VDR	  were	  shown	  to	  work	  synergistically	  to	  activate	  transcription	  of	  the	  osteoclast	  differentiation	  factor	  (ODF)	  gene	  in	  mice.	  Kabe	  et	  al.	  determined	  that	  transcriptional	  activation	  of	  the	  ODF	  gene	  by	  vitamin	  D	  required	  the	  presence	  of	  the	  CCAAT	  box.	  Moreover,	  NF-­‐Y	  was	  required	  to	  recruit	  RNA	  Pol	  II	  to	  the	  promoter	  region	  [64].	  In	  HeLa	  cells	  (cervical	  cancer	  cell	  line),	  the	  transcription	  factors	  SP1	  and	  AP-­‐1	  as	  well	  as	  the	  CCAAT	  box	  have	  been	  shown	  to	  be	  important	  for	  the	  transcriptional	  activation	  of	  the	  NRP-­‐1	  gene	  [63].	  There	  is	  little	  work	  characterizing	  the	  transcriptional	  regulation	  of	  NRP-­‐1	  in	  human	  immune	  cells,	  however,	  and	  there	  is	  no	  literature	  on	  the	  regulation	  of	  NRP-­‐1	  expression	  in	  UCB.	  To	  understand	  the	  molecular	  mechanism	  by	  which	  vitamin	  D	  increases	  the	  expression	  of	  NRP-­‐1	  in	  UCB,	  we	  performed	  an	  NCBI	  Gene	  search,	  finding	  multiple	  VDRE’s	  within	  the	  NRP-­‐1	  gene.	  We	  hypothesize	  that	  upon	  supplementation	  of	  vitamin	  D,	  the	  VDR	  may	  bind	  a	  VDRE	  within	  the	  NRP-­‐1	  gene	  to	  activate	  gene	  transcription.	  Efforts	  to	  determine	  if	  vitamin	  D	  effects	  NRP-­‐1	  at	  the	  transcriptional	  level	  are	  underway.	  We	  incubated	  whole	  UCB	  for	  up	  to	  24	  hours	  with	  or	  without	  the	  addition	  of	  vitamin	  D.	  NRP-­‐1	  mRNA	  levels	  will	  be	  assessed	  by	  RT-­‐PCR.	  If	  vitamin	  D	  acts	  at	  the	  transcription	  level	  to	  increase	  the	  expression	  of	  NRP-­‐1,	  then	  we	  should	  see	  an	  increase	  in	  NRP-­‐1	  mRNA	  by	  RT-­‐	  PCR	  in	  vitamin	  D	  treated	  UCB.	  If	  vitamin	  D	  has	  no	  effect	  on	  NRP-­‐1	  at	  the	  transcription	  level,	  we	  will	  evaluate	  the	  effect	  of	  vitamin	  D	  on	  NRP-­‐1	  at	  the	  protein	  level.	  We	  can	  incubate	  whole	  UCB	  overnight	  with	  or	  without	  the	  addition	  of	  vitamin	  D	  and	  then	  run	  a	  western	  blot	  probing	  for	  NRP-­‐1.	  If	  vitamin	  D	  acts	  at	  the	  protein	  level	  to	  increase	  the	  expression	  of	  NRP-­‐1,	  then	  we	  should	  see	  an	  increase	  in	  the	  amount	  of	  NRP-­‐1	  protein	  by	  western	  blot	  in	  vitamin	  D	  treated	  UCB.
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In	  conclusion,	  by	  using	  an	  ex	  vivo	  human	  UCB	  culture	  system	  we	  determined	  that	  vitamin	  D	  has	  a	  positive	  effect	  on	  human	  Treg	  differentiation.	  Additionally,	  our	  data	  suggest	  that	  vitamin	  D	  enhances	  Treg	  differentiation	  by	  increasing	  the	  expression	  of	  the	  monocyte	  cell	  surface	  molecules	  NRP-­‐1	  and	  LAP	  and	  by	  promoting	  co-­‐localization	  between	  NRP-­‐1	  and	  CD14	  as	  well	  as	  NRP-­‐1	  and	  CD36.	  Our	  data	  predict	  that	  the	  co-­‐localization	  between	  these	  molecules	  is	  important	  for	  the	  activation	  of	  TGF-­‐β	  and	  therefore	  the	  differentiation	  of	  Tregs	  in	  our	  culture	  system.	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